Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > COLUMN
COLUMN
- Maurer's Healthcare Insight (37)
January 20, 2003
- Maurer's Healthcare Insight (36)
December 2, 2002
- Maurer's Healthcare Insight (35)
November 11, 2002
- Maurer's Healthcare Insight (33)
September 2, 2002
- Maurer's Healthcare Insight (32)
August 5, 2002
- Maurer's Healthcare Insight (31)
July 22, 2002
- Maurer's Healthcare Insight (30)
July 1, 2002
- Maurer's Healthcare Insight (29)
June 3, 2002
- Maurer's Healthcare Insight (28)
May 20, 2002
- Maurer's Healthcare Insight (27)
April 29, 2002
- Maurer's Healthcare Insight (27)
April 15, 2002
- Maurer's Healthcare Insight (26)
March 18, 2002
- Maurer's Healthcare Insight (25)
February 25, 2002
- Maurer's Healthcare Insight (20)
September 17, 2001
- Maurer's Healthcare Insight (19)
September 3, 2001
- Maurer's Healthcare Insight(18)
August 6, 2001
- Maurer's Healthcare Insight (17)
July 16, 2001
- Maurer's Healthcare Insight (16)
June 25, 2001
- Maurer's Healthcare Insight (15)
May 21, 2001
- Maurer's Healthcare Insight (14)
April 23, 2001
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…